| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 19.64% | — | — |
| Operating Margin | — | — | — | -3741.48% | — | — |
| EBITDA Margin | — | — | — | -3678.60% | — | — |
| Net Margin | — | — | — | -3733.11% | — | — |
| Current Ratio | 4.88 | 6.05 | 1.82 | 7.19 | 32.43 | — |
| Quick Ratio | 4.88 | 6.05 | 1.82 | 7.19 | 32.43 | — |
| Debt / Equity | — | — | — | — | — | — |
| ROE | -114.61% | -134.70% | -343.85% | -80.55% | -17.11% | 27.54% |
| ROA | -96.20% | -115.93% | -204.45% | -68.76% | -16.60% | -76.34% |
| Asset Turnover | — | — | — | 0.02 | — | — |
| Book Value / Share | 13.31 | 31.24 | 2.64 | 0.57 | 2.39 | — |
Bluejay Diagnostics Inc. is a medical technology company focused on developing and marketing rapid diagnostic solutions for use in clinical settings. The company specializes in minimally invasive point-of-care tests and devices designed to provide timely, lab-quality biomarker results near the patient, supporting faster clinical decision-making in critical care environments. Its flagship Symphony platform is a near-patient biomarker detection system aimed at conditions where early and precise measurement of inflammatory and infectious markers can guide treatment. Bluejay Diagnostics primarily targets the infectious disease, inflammation, and oncology markets, working to enable more efficient triage and monitoring of patients in emergency departments, intensive care units, and other acute-care settings. Headquartered in Acton, Massachusetts and founded in 2015, the company operates within the health technology sector and the medical specialties industry, serving healthcare providers seeking to streamline workflows and improve access to actionable diagnostic information at or near the point of care.